The NEFA assay from Wako Diagnostics is designed to detect a variety of non-esterified fatty acids (NEFA). The test is specific to free fatty acids with minimal interferences from other related compounds and serum components such as bilirubin, hemoglobin, and ascorbic acid. The need for an extraction step has been eliminated. The company’s enzymatic method relies upon the acylation of coenzyme A and ultimately results in a purple colored product that can be measured colorimetrically at 550 nm.
The Autokit CH50 assay from Wako Diagnostics is a fully automated liposome – based assay for the determination of total complement activity in human serum. This proven and widely used methodology can be applied to most automated chemistry analyzers to evaluate deficiency or abnormalities of the complement system. The homogenous size of liposomes gives a stable dispersion. This, along with a fast, 10 minute total reaction time and ease of use makes it the best choice for your lab.
SynAbs is proud to appoint LuBioSience as its new distributor for Switzerland. LuBioScience has a seasoned team and expertise in selling biochemicals, including the specific monoclonal antibodies of SynAbs, in particular the anti-species which should be welcomed by the Swiss Biopharma R&D and IVD sector.
RARITAN, N.J. – July 21, 2017 – Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced that Ortho’s VITROS® Immunodiagnostic Products Insulin Reagent and Calibrators have received CE Mark, broadening Ortho’s menu of tests that manage all aspects of diabetes and other pancreatic disorders. An important biomarker in diabetes and pre-diabetes testing, the assay is expected to be commercially available for use on all of Ortho’s VITROS® Immunodiagnostic and Integrated Systems in Europe and other countries accepting the CE Mark during the third quarter of this year.
According to the World Health Organization; diabetes affects nine percent of people 18 years or older worldwide.i What’s more, 191 million people with diabetes are currently undiagnosed.ii Diabetes is managed as a chronic, lifelong condition with several significant co-morbidities, so it is vital that laboratories have a partner that supports the continuum of diabetes diagnostics.
“Our goal
Uniflex- Healthcare Packaging, a division of the Uniflex/ S.Walter Packaging company has announced it will be returning to the the AACC 2017 meeting in San Diego, California during July 31-August 3rd, 2017. They will be located at booth 519 at the San Diego Convention Center during the annual meeting. Uniflex has historically been an industry leader and supplier of medical packaging products for 50+ years, and introduced to the market place the liquid-tight adhesive seal specimen bag, the UniVault (R) patient valuables bags, and recently launched its new Lab Shield (R) "Removable-Biohazard" specimen bag. Much excitement surrounds this new product line!
Monoclonal antibodies development has been limited for a long time to only two species : mice and rats. However, the immune systems of mice and rats are not the most suitable in terms of humoral response to certain antigens, such as human antigens like glucagon. Indeed, the protein sequence of glucagon is the same in mice, rats and human (fig. 1). Small not immunogenic antigens, such as antibiotics or toxins, generally failed to trigger an immune response in such species. This is why some companies have developed fusion cell lines to generate monoclonal antibodies in rabbit (Abcam-Epitomics) or in sheep (Bioventix). However, these two tools are not totally satisfactory whether in terms of cost, stability or productivity.
The Immunologicals Group of The Binding Site is pleased to announce the launch of a number of new monoclonal antibodies and recombinant antigens focused on a variety of infectious/contagious disease states – including Cytomegalovirus (CMV), Hepatitis, HIV, Rubella, Syphilis, and Toxoplasmosis.
Dawn Foster, Founder/CEO of Staff Icons, a Global Scientific Recruitment Firm. She brings to the table 25 years of recruiting industry experience. Dawn holds a Bachelor’s Degree in Business Marketing and comes from a family of entrepreneurs. The recruitment niche she tapped into was due to the high demand of Scientists globally and she felt that recruitment services focusing within the scientific arena were much needed. She has built a reputation within the industry as the go-to Recruitment firm for Scientists of all levels. Dawn is passionate about contributing to the industry by finding Scientists career opportunities globally and helping clients find the best talent across the board.
Liquid biopsy is a new technology for detection and analysis of biomarkers in blood or other body fluids without the need of invasive procedures. One important analyte is cell-free circulating DNA (cfDNA). The main challenges in working with cfDNA are the low concentration (1 - 50 ng/ml) and the high degree of fragmentation of cfDNA (< 500 bp). An additional complication is that the circulating tumor DNA only accounts for up to 20 % of the total cfDNA. Therefore processing higher sample volumes, typically in the range of several milliliters, is required.
As companies and institutions from across the globe converge on San Diego for the annual ACCC meeting there is a common thread between them all – there is a drastic need for more trained professionals.
SynAbs is proud to announce strategic deal with successful company Dianova. Dianova has already demonstrated a huge knowledge and expertise in monoclonal antibodies and will consequently extend its catalogue with unique mAbs references from SynAbs. Under the terms of the agreement, Dianova will have access to unique portfolio of rats and guinea pigs mAbs to address German territory needs in R&D and IVD fields.
The Diatron, global provider of hematology and clinical chemistry analyzers, will display their Aquila 3-part differential hematology analyzer (60 samples /hour throughput) at the upcoming AACC Meeting in San Diego, California on the 1-3 of August, 2017.
Findings presented at the American Society for Microbiology’s ASM Microbe conference show that the ultra-sensitive Clostridium difficile toxin A/B assay in development for use on the Sgx Clarity™ system offers excellent sensitivity and may be a critical tool for improving the diagnosis of this life-threatening infection. The Sgx Clarity system is a fully-automated, in vitro diagnostics platform powered by Single Molecule Counting technology.
Yaskawa Motoman offers track-based specimen processing solutions that improve speed, capacity and accuracy for labor-intensive, high throughput areas of the clinical diagnostic lab. These fully integrated pre- and post-analytic automation solutions can enable high throughput with minimal staffing.
Singulex, a global immunodiagnostics company pioneering ultra-sensitivity in the precision measurement of protein biomarkers, today announced it has applied the CE Mark to its ultra-sensitive troponin I assay (cTnl), the first offered on the Sgx Clarity® system, a fully-automated, in vitro diagnostics platform powered by Single Molecule Counting technology.
RSS